Pharmaron Beijing Co Ltd
HKEX:3759

Watchlist Manager
Pharmaron Beijing Co Ltd Logo
Pharmaron Beijing Co Ltd
HKEX:3759
Watchlist
Price: 20.58 HKD -2% Market Closed
Market Cap: HK$58.9B

EV/EBIT

25.3
Current
8%
Cheaper
vs 3-y average of 27.6

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
25.3
=
Enterprise Value
HK$54.4B
/
EBIT
¥2.1B

Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBIT
25.3
=
Enterprise Value
HK$54.4B
/
EBIT
¥2.1B

Valuation Scenarios

Pharmaron Beijing Co Ltd is trading below its 3-year average

If EV/EBIT returns to its 3-Year Average (27.6), the stock would be worth HK$22.41 (9% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+30%
Average Upside
15%
Scenario EV/EBIT Value Implied Price Upside/Downside
Current Multiple 25.3 HK$20.58
0%
3-Year Average 27.6 HK$22.41
+9%
5-Year Average 32.9 HK$26.79
+30%
Industry Average 26.8 HK$21.76
+6%
Country Average 28.9 HK$23.51
+14%

Forward EV/EBIT
Today’s price vs future ebit

Today's Enterprise Value EBIT Forward EV/EBIT
HK$54.4B
/
Jan 2026
¥2.1B
=
25.3
Current
HK$54.4B
/
Dec 2026
¥2.7B
=
20.5
Forward
HK$54.4B
/
Dec 2027
¥3.2B
=
17.1
Forward

Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.

Peer Comparison

All Multiples
EV/EBIT
P/E
All Countries
Close
Market Cap EV/EBIT P/E
CN
Pharmaron Beijing Co Ltd
HKEX:3759
52.7B HKD 25.3 31.7
US
PerkinElmer Inc
LSE:0KHE
1T USD 2 361.7 4 280.5
US
Thermo Fisher Scientific Inc
NYSE:TMO
176.7B USD 24.7 26.4
US
Danaher Corp
NYSE:DHR
125.4B USD 25.9 34
KR
Samsung Biologics Co Ltd
KRX:207940
82.3T KRW 39.4 46.1
CN
WuXi AppTec Co Ltd
SSE:603259
298.9B CNY 16.3 15.6
CH
Lonza Group AG
SIX:LONN
34.3B CHF 25.4 -118.2
US
Agilent Technologies Inc
NYSE:A
32.7B USD 22 25.3
US
Waters Corp
NYSE:WAT
30.4B USD 38.4 47.3
US
IQVIA Holdings Inc
NYSE:IQV
27.5B USD 17.2 20.3
US
Mettler-Toledo International Inc
NYSE:MTD
26.1B USD 24.7 30

Market Distribution

In line with most companies in China
Percentile
51st
Based on 5 337 companies
51st percentile
29.8
Low
0 — 16.6
Typical Range
16.6 — 52.9
High
52.9 —
Distribution Statistics
China
Min 0
30th Percentile 16.6
Median 28.9
70th Percentile 52.9
Max 49 021

Pharmaron Beijing Co Ltd
Glance View

Pharmaron Beijing Co Ltd., a dynamic player in the biotech and pharmaceutical services sector, has carved a niche by capitalizing on the demand for comprehensive R&D services. Founded in 2004, the company emerged at a time when global pharmaceutical companies were grappling with skyrocketing research costs and the increasing complexity of drug development. Pharmaron offers a broad spectrum of services across the drug discovery and development pipeline, including laboratory services, chemistry, biology, and pharmacology, effectively monetizing its expertise by partnering with global pharmaceutical firms. By providing integrated solutions that cover the entire span of research, from preclinical development to commercial manufacturing, Pharmaron positions itself as an indispensable ally for companies aiming to streamline their product development journeys. The company’s revenue model thrives on long-term partnerships and collaborations with some of the industry's leading pharmaceutical and biotech firms. Using a client-centric approach, Pharmaron aligns its capabilities with customer needs, ensuring scalable and customizable service offerings. This close alignment not only enhances client satisfaction but also encourages repeat business, fostering a cycle of sustainable revenue growth. In recent years, Pharmaron has been expanding its geographical footprint and service capacity through strategic acquisitions and investments in state-of-the-art facilities and technologies, aiming to bolster its position in key markets across the US, Europe, and China. As the pharmaceutical landscape continues to evolve, Pharmaron leverages its robust R&D service portfolio and strategic alliances to maintain its growth trajectory amidst a backdrop of increasing globalization and technological advancement in the industry.

Intrinsic Value
28.82 HKD
Undervaluation 29%
Intrinsic Value
Price HK$20.58
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett